<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460654</url>
  </required_header>
  <id_info>
    <org_study_id>MGH-988</org_study_id>
    <nct_id>NCT01460654</nct_id>
  </id_info>
  <brief_title>Testosterone and Alendronate in Hypogonadal Men</brief_title>
  <official_title>Testosterone and Alendronate in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the hypothesis that the combination of testosterone replacement
      and alendronate will improve bone density and parameters of bone quality more than either
      medication alone in older men with low testosterone levels and low bone density.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spine Bone Mineral Density by DXA</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Testosterone and Placebo Alendronate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate and Placebo Testosterone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone and Alendronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testosterone Gel (Fortesta) 40mg daily.</description>
    <arm_group_label>Testosterone and Placebo Alendronate</arm_group_label>
    <arm_group_label>Testosterone and Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronate (Fosamax) 70mg every week.</description>
    <arm_group_label>Alendronate and Placebo Testosterone</arm_group_label>
    <arm_group_label>Testosterone and Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Alendronate</intervention_name>
    <description>A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.</description>
    <arm_group_label>Testosterone and Placebo Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Testosterone</intervention_name>
    <description>Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.</description>
    <arm_group_label>Alendronate and Placebo Testosterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex

          -  Age 60 or above

          -  Testosterone &lt;300 ng/dL

          -  DXA T score &lt; -1 OR FRAX Score of 3% or greater for hip fracture or 20% or greater for
             major osteoporotic fracture

        Exclusion Criteria:

          -  Significant liver or kidney disease

          -  Elevated prolactin level

          -  Abnormal TSH

          -  Abnormal 25-Vitamin D

          -  PSA &gt; 2.5

          -  History of malignancy

          -  Calcium &gt; 10.6

          -  Alkaline Phosphatase &gt; 150

          -  Fracture within the last 6 months

          -  History of acute urinary retention

          -  Hematocrit &lt; 32% or &gt; 50%

          -  Fracture within the past 6 months

          -  American Urological Association BPH symptom index &gt; 21

          -  Sleep apnea

          -  Abnormalities of the esophagus which delay esophageal emptying

          -  Significant cardiopulmonary disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Benjamin Leder, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

